XM-ONE® non-HLA crossmatching provides additional information compared to the currently used lymphocyte crossmatch tests and therefore improves the basis for risk assessment prior to kidney transplantation.
The study showed that the XM-ONE® test can detect an antibody population not possible to detect with lymphocyte crossmatch tests that is strongly associated with rejection episodes and reduced kidney function after transplantation. Thus the XM-ONE® test can identify patients at risk of antibody-mediated rejections.